Watch the whole program

Deal Valuation

This month, PharmaVentures Business Review focuses on deal valuation. We explore some of the trends in overall deal value as well as the technical methodologies used for deal valuation. Our panel of industry experts discusses the key issues that companies must consider when negotiating deals in order to attain maximum value. We also have the usual round-up of key deals and transactions that have taken place in the last month.

To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.

• ARYx Therapeutics' and Procter & Gamble Pharmaceuticals' strategic partnership for new treatments for gastrointestinal disorders
• Archemix's and Elan's autoimmunity alliance in aptamer therapeutics
• The collaboration between Roche and Actelion to develop novel autoimmune disorder therapeutics
• Genentech's and Inotek Pharmaceuticals' collaboration to discover new cancer drugs
• Enzon Pharmaceuticals' oncology therapeutics deal with Santaris Pharma

Watch this segment

The Month in Review

Key deals and transactions from the past month are presented by the latest addition to the PharmaVentures Business Review team, Ann Salter. We cover the following deals:

To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.

• ARYx Therapeutics' and Procter & Gamble Pharmaceuticals' strategic partnership for new treatments for gastrointestinal disorders
• Archemix's and Elan's autoimmunity alliance in aptamer therapeutics
• The collaboration between Roche and Actelion to develop novel autoimmune disorder therapeutics
• Genentech's and Inotek Pharmaceuticals' collaboration to discover new cancer drugs
• Enzon Pharmaceuticals' oncology therapeutics deal with Santaris Pharma

Watch this segment

The Business Report

In this month's Business Report, we assess the valuation methodologies used in deal transactions for assets such as drugs in development, whole pipelines or business assets. We use data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, to look briefly at some of the trends in shifting deal values for licensing deals and for products in different therapeutic areas.

Watch this segment

Meet the Experts

This month, Fintan Walton leads our expert panel in a discussion about deal valuation, further exploring the risks and benefits associated with the different methodologies outlined in the business report.

On this month's panel:

Scott Gorman,
VP Business Development, PharmaVentures

Ian Nicholson,
CEO Chroma Therapeutics